Montes Archimedes Acquisition Corp (MAAC) to Combine with Roivant Sciences in $5Bn Deal

Montes Archimedes Acquisition Corp (MAAC) to Combine with Roivant Sciences in $5Bn Deal

Montes Archimedes (NASDAQ:MAAC) has entered into a definitive agreement to combine with biotech firm Roivant Sciences at an enterprise value of $5 billion. Basel, Switzerland-based Roivant develops an array of drug candidates acquired from peers or internally developed with its enhanced computing platform. The combined company is expected to trade on the Nasdaq under the
Read More
To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.